Navigation Links
InterMune Announces Submission of MAA for Pirfenidone for the Treatment of Patients With IPF
Date:3/2/2010

ts, data had previously been presented from another Phase 3 study and three Phase 2 clinical trials in more than 400 patients which suggested that pirfenidone may positively affect lung function and disease progression in patients with IPF.  In those clinical studies, pirfenidone was safe and generally well tolerated, with the most frequent side effects reported being photosensitivity rash and gastrointestinal symptoms.  In October of 2008, pirfenidone was approved for use in IPF patients in Japan and is marketed as Pirespa® by Shionogi & Co. Ltd. in that country.

About IPF

Idiopathic pulmonary fibrosis (IPF) is a disabling and ultimately fatal disease that affects approximately 200,000 people in Europe and the United States combined, with approximately 30,000 new cases reported per year in each region.

IPF is characterized by inflammation and scarring (fibrosis) in the lungs, hindering the ability to process oxygen and causing shortness of breath (dyspnea) and cough and is a progressive disease, meaning that over time, lung scarring and symptoms increase in severity.  The median survival time from diagnosis is two to five years, with a five-year survival rate of approximately 20%.  Patients diagnosed with
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
6. InterMune to Present at the SIGnificant Options in Healthcare Conference
7. Evotec Expands Collaboration With InterMune
8. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
9. InterMune to Present at Deutsche Bank Health Care Conference
10. InterMune to Present at Bank of America Health Care Conference
11. InterMune to Present at Citigroup Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)...  Neurotech Pharmaceuticals, Inc., announced today the first ... 2 clinical trial of NT-503 Encapsulated Cell Therapy ... choroidal neovascularization secondary to age related macular degeneration ... growth factor (VEGF) receptor protein continuously produced by ... proof-of-concept study will evaluate NT-503 ECT as a ...
(Date:9/2/2015)... ZIONA, Israel , September 2, 2015 /PRNewswire/ ... today announced the intent of the National Institute of Allergy ... of Health (NIH) within the Department of Health and Human ... be held in the United States ... of BiondVax,s universal flu vaccine candidate, Multimeric-001 (M-001), as a ...
(Date:9/2/2015)... ... 02, 2015 , ... The TS5-Q is designed for myriad ... to analysis of athletic performance. Producing high-resolution slow-motion video , the TS5-Q ... process with the naked eye. , Slow motion sequences are commonly seen ...
(Date:9/1/2015)... 2015  ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ), ... of targeted antiviral therapies, announced today that it will ... Annual Global Investment Conference sponsored by H.C. Wainwright ... The St. Regis Hotel in New York, ... , Chief Executive Officer, will provide an overview of ...
Breaking Biology Technology:Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 2Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 3ContraVir to Present at Rodman & Renshaw 17th Annual Global Investment Conference 2
... DURHAM, N.C., Dec. 16 Parion Sciences, Inc., ... from the failure of the body,s mucosal defenses, ... have awarded the,company a biodefense grant in excess ... The purpose of the grant is to ...
... KRAS Biomarker PresentsPotential toPersonalize Colorectal Cancer Treatment Determining Who ... , THOUSAND OAKS, Calif., Dec. 16 Amgen ... discuss the clinical utility of the KRAS ... colorectal cancer (mCRC) treated with anti-epidermal growth factor receptor ...
... 16 , - ... The American Journal of Medicine (AJM), one of ... Medicine blog,( http://amjmed.blogspot.com ), a dynamic forum where physicians and ... that have been published in the Journal. , ...
Cached Biology Technology:Parion Sciences Receives NIH Biodefense Grant to Study Novel Methods for Mitigating Radiation-Induced Lung Injury 2Parion Sciences Receives NIH Biodefense Grant to Study Novel Methods for Mitigating Radiation-Induced Lung Injury 3Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting 2Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting 3Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting 4Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting 5Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting 6Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting 7Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting 8Elsevier Introduces The American Journal of Medicine Blog 2Elsevier Introduces The American Journal of Medicine Blog 3
(Date:8/24/2015)... , Aug. 24, 2015  Based on its recent ... DERMALOG with the 2015 African Biometrics Company of the Year ... achieved substantial commercial success in Africa . ... , where it has implemented one of the largest biometric ... as well as the Central Bank of Nigeria ...
(Date:8/18/2015)... , Aug. 18, 2015  Navitas ... key contributor to the Submission Content Management ... IRISS, a non-profit forum. Dedicated to the Implementation ... a neutral platform for industry, vendors, health ... information and work towards a standard method ...
(Date:8/12/2015)... YORK , Aug. 12, 2015  New ... hackers can attack Android phones to steal users, ... the increasing availability of fingerprint scanners on mobile ... utmost concern. To secure biometrics on mobile devices, ... to augment these convenient authentication systems with strong ...
Breaking Biology News(10 mins):Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 2Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 3Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 4Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 5Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 6Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3
... Protein Society, the leading international society devoted to furthering ... Protein Science , announce the second annual selection of ... Annual Symposium of The Protein Society (July 27-30, 2014, ... the outstanding contributions for which they are being recognized, ...
... boss loves Atkins. Your sister is gluten-free, and your roommate is ... are. In new research published this month in Cell ... collection of genes that allow an organism to adapt to different ... can cause premature aging and death. Finding a genetic basis ...
... Hospital scientists have discovered a promising new class of ... tuberculosis (TB), a global killer. The drugs increased survival ... drug-resistant strains of TB. St. Jude led the international ... issue of the journal Nature Medicine . ...
Cached Biology News:Scientists find genetic mechanism linking aging to specific diets 2Promising class of antibiotics discovered for treatment of drug-resistant tuberculosis 2